Using Preimplantation Genetic Screening (PGS) to Optimize Elective Single Embryo Transfer (eSET)



Eric J. Forman, M.D., HCLD

Medical & Laboratory Director

Center for Women's Reproductive Care at Columbia University



Objectives

- To discuss the advantages and safety benefits of elective single embryo transfer (eSET)
- To review the limitations of morphology-based selection for eSET
- To summarize the development of a validated technology for preimplantation genetic screening (PGS)
- To highlight future directions to further enhance safety and efficacy of IVF

Singleton Term Delivery: The Ideal IVF Outcome

- IVF twin pregnancies are at an increased risk of: — Preeclampsia (2-fold risk increase)¹
 - Extreme prematurity (7.4-fold increase delivery <32 wks)²
 - NICU admission (3.8-fold increased risk)²
 Perinatal Death (2-fold increase)²
- Two IVF singleton deliveries have better obstetrical outcomes than one IVF twin delivery³
 - 1. ASRM Practice Committee, *Fertil Steril*, 2012. PMID: 22192352
 - 2. Pinborg A, et al., Acta Obstet Gynecol Scand, 2004. PMID: 15488125
 - 3. Sazonova A ,et al., Fertil Steril, 2013. PMID: 23219009

Multiple Births Increase the Psychological Burden of Infertility Care

Prevalence (%) in outcomes by multiplicity in full-term births: purple = singletons; green = twins; turquoise = triplets. *P <.05, **P <.001.



ASRM Guidelines Do Not Eliminate Multiples

TABLE1

Recommended limits on the numbers of embryos to transfer.

		Age							
Prognosis	< 35 yrs	35–37 yrs	38–40 yrs	41–42 yrs					
Cleavage-stage	embry	os ^a							
Favorableb	1–2	2	3	5					
All others	2	3	4	5					
Blastocysts ^a									
Favorable ^b	1	2	2	3					
All others	2	2	3	3					

^a See text for more complete explanations. Justification for transfering one additional embryo more than the recommended limit should be clearly documented in the patient's medical record.

^b Favorable = first cycle of IVF, good embryo quality, excess embryos available for cryopreservation, or previous successful IVF cycle.

Practice Committee Number of Embryos Transferred. Fertil Steril 2009.

•Nearly half of all babies born after IVF are part of a multiple birth¹

•A mandatory SET policy for good-prognosis patients still resulted in a 19% multiple pregnancy rate²

1. MMWR Surveil Summ., 2009. PMID: 19521336

2. Ryan GL et al., Fertil Steril, 2007. PMID: 17490657

ORIGINAL ARTICLE

Fertility Treatments and Multiple Births in the United States



Kulkarni D et al, New Engl J Med, 2014. PMID: 24304051

Single embryo transfer is rare in the U.S.

Percentage of IVF cycles with eSET



Source: Sart.org

Why not transfer a single embryo every time?



How many failures before Louise Brown & Elizabeth Carr?



40th attempt was ectopic <u>104th</u> attempt Louise was born



41 natural cycles

13 hMG stimulations

54th attempt Elizabeth was born

FRESH SET RESULTS IN LOWER DELIVERY RATES THAN DOUBLE EMBRYO TRANSFER (DET)



- Cochrane Review of 6 randomized trials from 1999-2006 (N = 1,257)
- Young, good prognosis patients with "top quality" embryos available
- Slightly more singletons after DET

Single blastocyst transfer: a prospective randomized trial

David K. Gardner, D.Phil., Eric Surrey, M.D., Debra Minjarez, M.D., Annette Leitz, L.P.N., John Stevens, B.S., and William B. Schoolcraft, M.D.



- 95% CI of Risk Difference¹: -41% to +11%
- RCT of single blast vs. single cleavage (32% vs. 22% delivery rate)²
- Did not significantly impact clinical practice as eSET still underutilized
 - 1. Gardner DK et al, Fertil Steril, 2004
 - 2. Papanikolaou EG et al, NEJM, 2006

Success Rates and Acceptability of eSET

Table IV. Attitudes towards elective single embryo transfer (e	SET)			
	Control max $n = 62$	Information leaflet max $n = 66$	Discussion max $n = 61$	P-value
Would elective single embryo transfer (eSET) be acceptable if this meant slightly reduced pregnancy rates?				
Yes Would eSET be more acceptable if this reduced the number	17/51 (27%)	20/66 (30%)	24/17 (32%)	0.39
of twins? Yes	25/61 (40%)	32/66 (49%)	26/61 (43%)	0.76
Would eSET be acceptable if the success rate was the same as DET?				
Yes	51/62 (82%)	55/66 (83%)	53/61 (87%)	0.76
Would finances affect your decision to have SET? Yes	16/62 (26%)	17/65 (26%)	19/61 (31%)	0.80
Would eSET be acceptable if the cost was fixed regardless of the number of cycles?	25 (6) ((57))	26165 (550)	20150 ((50))	0.72
Would your opinion change if you were charged for the	35/61/(5/%)	30/03 (33%)	38/38 (63%)	0.73
Nospital care of premature twins? Yes	17/61 (27%)	20/64 (31%)	19/59 (31%)	0.69

Murray S et al, Hum Reprod, 2004







N=132,874 Mature Follicles

What might explain the high failure rate?



Embryos have a high risk of aneuploidy



The risk of twins remains high even among older patients not traditionally offered eSET



The proportion of live births after IVF in the United States that were twin births. The twin delivery rate has remained stable across age groups from 2004 to 2011.

Source: Society for Assisted Reproductive Technology

SET delivery rate ≈ Implantation Rate



Double embryo transfer (DET) results in higher delivery rates



DET usually results in more singletons



...At the cost of more twins



Aneuploidy screening can only improve outcomes if morphology is sometimes selected against...

SET Based on Embryo Morphology





SET Based on Aneuploidy Screening and Embryo Morphology

FISH for Aneuploidy Screening

	PGS Control Study or Subgroup Events Total Events Total Weight Risk Difference	Risk Difference, 95% CI
	Indication Advanced Maternal Age M-H, Fixed, 95% CI Stasseen 2004 21 199 29 199 36 6% 0.05 [0.11.0.02]	
ALC ROOM	Mastenbriek 2007 49 206 71 202 38.4% -0.11 [-0.20, -0.03] Hardarson 2008* 3 56 10 53 10.3% -0.14 [-0.26, -0.01] Schoolcraft 2008 16 32 16 30 5.8% -0.03 [-0.28, 0.22]	
The NEV	V ENGLAND L of MEDICINE	•
ESTABLISHED IN 1812	JULY 5, 2007 VOL. 357 NO. 1	-
In Vitro Fertilization wit Sebastiaan Mastenbroek, M.Sc., Birgit Sikkema-Raddatz, Ph.D., Johanna C. Eus G.J.M. Arts, Ph.D., Jan W.A. de Vries Maas Jan Heineman, M.D., Ph.D., S	h Preimplantation Genetic Screening Moniek Twisk, M.D., Jannie van Echten-Arends, Ph.D., Korevaar, Ph.D., Harold R. Verhoeve, M.D., Niels E.A. Vogel, M.D, , Ph.D., Patrick M. Bossuyt, Ph.D., Charles H.C.M. Buys, Ph.D., joerd Repping, Ph.D., and Fulco van der Veen, M.D., Ph.D.	
	Indication Repeated Implantation Failure M-H, Fixed, 95% CI Biockeel 2008 15 72 26 67 100.0% -0.18 [-0.33, -0.03] Subtotal (95% CI) 72 67 100.0% -0.18 [-0.33, -0.03] Total events 15 (21%) 26 (39%) 26 (39%)	ŧ
	Heterogeneity: Not applicable Test for overall effect: Z = 2.35 (P = 0.02)	-0.5 -0.25 0 0.25 0.5 Favours Control Favours PGS

Anything can be done "sub-optimally"

Mastenbroek S et al, Hum Reprod Update, 2013. PMID: 21531751

Limitations of FISH-based PGS

Impact of the biopsy

- Could potentially outweigh benefit of selection
- Safety not previously evaluated rigorously



Polar Body Biopsy

Blastomere Biopsy

Trophectodem Biopsy

A trophectoderm biopsy

https://www.youtube.com/watch?v=FHBuwaE1CEM



Does Embryo Biopsy Impact the Developmental Potential of the Oocyte

Routine IVF Care through Retrieval



Identify mature oocytes

ICSI, culture, and select 2 best embryos for transfer

Transfer the embryos



Cell submitted for eventual aneuploidy screening and fingerprinting



One embryo randomized to undergo biopsy

Implantation, Maternal serum sampling for free fetal DNA and Fingerprinting

N=113 pairs; 226 embryos

SEMINAL CONTRIBUTION

Cleavage-stage biopsy significantly impairs human embryonic implantation potential while blastocyst biopsy does not: a randomized and paired clinical trial

Richard T. Scott Jr., M.D.,^{a,b} Kathleen M. Upham, B.S.,^a Eric J. Forman, M.D.,^b Tian Zhao, M.S.,^a and Nathan R. Treff, Ph.D.^{a,b,c}



*P<0.03, McNemar chi-square

Scott RT et al, Fertil Steril, 2013. PMID: 23773313

Limitations of FISH-based PGS

- Impact of the biopsy
 - Could this outweigh benefit of selection
 - Not previously evaluated rigorously
- Accuracy of PGS result
 - Does FISH result reflect true state of embryo?
 - Limited number of chromosomes probed with FISH
 - High error rate of single cells FISH

Accurate single cell 24 chromosome aneuploidy screening using whole genome amplification and single nucleotide polymorphism microarrays





Delivery Rate by Age Group for Control SET versus CCS-SET



© The Author 2012. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.

human reproduction

Timing Matters: Synchrony of the embryo and endometrium during IVF













Blastocyst Euploid Selective Transfer (BEST) Trial

- Non-Inferiority Randomized Controlled Trial
 - Primary outcome: Ongoing pregnancy to viable gestation
 (≥24 weeks) after 1st synchronous blastocyst-stage embryo transfer (fresh day 5 blastocysts or frozen 6 blastocysts)
 - Study Group:

Transfer single blastocyst after real-time qPCR based PGS

• Control Group:

Transfer best two blastocysts by traditional morphology

Trophectoderm Biopsy



IL Lysis & Trol Group Transfer best two blastocysts by traditional morphology criteria 384-Well Plate -All other good-quality blastocysts vitrified in pairs

Study Group

-All good-quality blastocysts undergo TE biopsy and PGS

-Transfer single best euploid

-All other euploid blastocysts vitrified individually

Cryopreserve

Do Not Tran 10 11 12 13 14 15 16

Do Not Transfe

Transter

Chromosom



PCR Heatmap

156 186 176 176 176 186 181 175 196 184 175 196 196 196 199 199 199 198 178 178 199			
1p15.2 1p80.13 1q25.2 1q32.1 2p16.3 2p23.3 2q21.2 2q24 8p14.1 3p21.2	2.17 2.3 3q11.2	1.83 1.94 3623	A
202 203 102 402 217 218 201 211 26 22 16 200 253 241 240 222 212 26 163 165 148 164 233 237 161 166 141 156 229 214 235 221 160 160 165 156 220 234 257 257	1.58 1.7	2 1.75 2.05	C
4912 49151 4923 491512 59141 59152 59213 59212 59241 59252 1931 186 2.35 2.38 1-12 1.43 1.61 2.11 2.55 2.54 2.67 2.60 2.55 2.31 1.95 2.00 2.55 2.35 2.69 2.50	0q13 1.86 1.7	3 2.27 2.16	D
135 170 107 139 130 205 180 139 179 136 138 208 141 51 157 164 201 213 135 205 79133 7914 7922 1 7913 992 9623 9623 9623 9623 9623 9623 9623	1.87 2.0 Pq21.13 2.06 1.9	2.30 2.49 9q22.33 4 2.60 2.63	F
225 228 166 168 178 178 178 178 179 189 255 240 265 231 350 257 215 171 183 180 111 36/231 - 56/11 56/23 166/21 16/23 17/13 180 111 247 241 146 24/255 178 258 255 253 214 244 279 25 271 181 179 123 179	2.12 2.2 12q12 1.95 2.1	4 2.03 2.05 12422 0 1.90 1.93	G H
130 1361 169 192 235 261 234 264 18412 442 4433 4443 4443 4443 4443 4443 44	1.70 1.7 18q25.1 5 ^{1.70} 1.7	3 5 09 1 00 15q28.1 4 5 01 5 25	I J
182 215 175 215 186 200 180 180 227 246 231 242 230 207 230 215 184 180 186 202 	2.12 2.0 16q21.33 2.03 2.1-	0 1.01 1.97 18q23 4 1.90 2.01	K L
216 229 247 246 227 229 469 245 247 200 229 220 469 245 247 256 148 256 247 255 148 256 248 256 248 256 256 256 256 256 256 256 256 256 256	1.72 1.9 21q22.11 1.60 1.6	5 1.94 1.95 21q22.13 1 1.82 1.82	M N
133 230 262 264 177 186 (14 26) 1111 146 160 06 161 161 16 2011 2012 27 2813 2813 28133 48122 4813 4812 481 481 481 481 481 481 481 481 481 481	10.00 (0.00) 10.11.000 (0.11.000)	Yq11.223	0 P

Single Euploid Blastocyst Selected for transfer

46.XX

47,XY+22

47,XY+18



Study flow of participants



TABLE 1

Characteristics of the patients.

Charac teristic	Single euploid blastocyst transfer ($n = 89$)	Double blastocyst transfer ($n = 86$)	P value
Age at oocyte retrieval, y			
Mean \pm SD	35.1 ± 3.9	34.5 ± 4.7	.5
Range	25.1-41.4	22.9-42.6	
Body mass index, kg/m ²			
Mean \pm SD	23.5 ± 3.5	23.8 ± 3.2	.4
Range	17.6-30.2	18.0-30.8	
Anti-Müllerian hormone level, ng/mL			
Mean \pm SD	3.5 ± 2.4	4.0 ± 3.5	.2
Range	1.2-18.0	1.2-22.0	
Day 3 FSH, IU/L			
Mean \pm SD	6.9 ± 1.8	6.6 ± 1.7	.2
Range	3.2-11.6	2.8-10.8	
Primary cause of infertility, n (%)			
Male factor	25 (28.1)	22 (25.6)	.9
Unexplained	24 (27.0)	24 (27.9)	
Ovulatory dysfunction	12 (13.5)	17 (19.8)	
Tubal factor	11 (12.4)	13 (15.1)	
Endometriosis	6 (6.7)	4 (4.7)	
Other	11 (12.4)	6 (7.0)	
History of previous pregnancies, n (%)	47 (52.8)	42 (48.8)	.6
Live birth	23 (25.8)	22 (25.6)	
Clinical miscarriage	25 (28.1)	14 (16.3)	
Termination of pregnancy	11 (12.4)	9 (10.5)	
History of prior treatment with IVF, n (%)	18 (20.2)	16 (18.6)	.8
Live birth	8 (9.0)	4 (4.7)	
Forman. Blastogst Euploid Selective Transfer (BEST) Trial Fertil Ster	2013.		

TABLE 2

Outcomes according to treatment group (intention-to-treat analysis).

Outcome	Single euploid blastocyst transfer ($n = 89$)	Double blastocyst transfer ($n = 86$)	P value
Total dose of gonadotropins, ampules			
Mean \pm SD	37.8 ± 12.9	37.0 ± 13.6	.7
Range	15.5-72	14.5-81	
E ₂ , pg/mL, at surge			
Mean \pm SD	2,437 ± 1,212	$2,540 \pm 1,236$.6
Range	513-6,267	605-6,000	
Retrieved oocytes			
Mean \pm SD	16.9 ± 8.4	15.7 ± 7.1	.6
Range	5-45	3–42	
Fertilized oocytes (two pronuclei)			
Mean \pm SD	11.1 ± 5.9	10.8 ± 5.7	.9
Range	4–30	3–33	
High-quality blastocysts			
Mean \pm SD	5.8 ± 3.6	5.3 ± 3.0	.5
Range	2–22	2–18	
Vitrified blastocysts			
Mean \pm SD	3.7 ± 2.9	3.9 ± 2.8	.5
Range	0-17	0–16	
Vitrified euploid blastocysts			
Mean \pm SD	3.2 ± 2.8	NA	
Range	0-17	NA	
Patients who received fresh ET (%)	60 (67)	61 (71)	.6
Patients who received frozen embryo transfer due to			
Embryo-endometrial dyssynchrony	22	20	
Ovarian hyperstimulation syndrome risk	5	3	
Hydrosalpinx	0	2	
Nondiagnostic result of embryo biopsy	1	0	
Forman. Blastocyst Euploid Selective Transfer (BEST) Trial. Fertil Steril 2013.			

Aneuploidy Rate of Transferrable Blastocysts



SART Age Group (Years)

Aneuploidy increases with increasing age (P<0.01) N=506 blastocysts, Overall aneuploidy rate = 31%

Delivery Rate Per Patient (n=175)

Single euploid blastocyst transfer (N=89)
 Untested 2-blastocyst transfer (N=86)

Proportion of Ongoing Pregnancies

Delivery Follow Up

REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY Obstetrical and neonatal outcomes from the BEST Trial: single embryo transfer with aneuploidy screening improves outcomes after in vitro fertilization without compromising delivery rates

Eric J. Forman, MD; Kathleen H. Hong, MD; Jason M. Franasiak, MD; Richard T. Scott Jr, MD

Delivery Follow Up

- Followed outcomes from 1st embryo transfer to delivery
- Encouraged patients who did not deliver to have a frozen transfer
- Lower risk of preterm delivery after euploid eSET: 13% vs. 29% (P=0.03)
- Nearly twice as likely to have a term, singleton delivery: 60% vs. 31% (P<0.001)

Better obstetrical outcomes

•Median Birthweight: 3,317g – Single euploid 2,778g – 2-Blastocyst (P<0.001) •Low birthweight (<2,500g): 11% (7/62) – Single Euploid 33% (30/92) – 2-Blastocyst (P=0.002)

Very low birthweight (<1,500g):
 0% (0/62) – Single Euploid
 7% (6/92) – 2-Blastocyst (P=0.08)

Better Obstetrical Outcomes Reduced Risk of NICU Admission

Euploid eSET: 93 total days spent in NICU

Untested 2-Embryo Transfer: 479 total days spent in NICU

Better Obstetrical Outcomes Reduced Risk of NICU Admission

Obstetrical Costs Likely Outweigh Additional ART Costs

Costs per Delivery*						
Singleton	\$21,458					
Twins	\$104,831					
Triplets	\$407,199					

Does not include:

- Disability costs during bed rest
- Loss of productivity in the work place

Fewer "Big Ticket" Hospital Admissions

Mean total hospital and IVF charges per delivery:

- \$73,407 (euploid eSET)
- \$111,488 (untested 2-ET)
 P=0.09
- ~33% reduction in costs per delivery
- A \$38,000 difference per IVF delivery would represent \$1.9 B savings on health care costs with ~50,000 IVF deliveries annually

PGS for whole chromosome aneuploidy improves IVF outcomes:

	PGS-C	CS	Contro	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Yang et al. 2012	39	55	22	48	13.3%	1.55 [1.09, 2.20]	
Forman et al. 2013	55	87	89	172	33.9%	1.22 [0.98, 1.52]	
Scott et al. 2013	107	134	103	163	52.7%	1.26 [1.09, 1.46]	-
Total (95% CI)		276		383	100.0%	1.29 [1.15, 1.45]	•
Total events	201		214				
Heterogeneity: Chi ² =	1.34, df =	2 (P = (0.51); I ² =	0%		_	
							0 E 0 7 E 7 E 7
Test for overall effect: ned implantation	Z = 4.27 (rate (>	P < 0.0 20 we	001) eks gest	ation)		0.5 0.7 1 1.5 2 Favours Control Favours PGS-CCS
Test for overall effect: ned implantation	Z = 4.27 (rate (> 2 PGS-C	P < 0.0 20 we	001) eks gest Contr	ation)	Risk Ratio	0.5 0.7 1 1.5 2 Favours Control Favours PGS-CCS
Test for overall effect: ned implantation Study or Subgroup	Z = 4.27 (rate (> 2 PGS-0 Events	P < 0.0 20 we CS Total	001) eks gest Contr Events	ation ol Total) Weight	Risk Ratio M-H, Fixed, 95% Cl	Risk Ratio M-H, Fixed, 95% CI
Test for overall effect: ned implantation Study or Subgroup Yang et al. 2012	Z = 4.27 (rate (> PGS-C Events 38	20 we CS Total 55	001) eks gest Contr Events 20	ation ol <u>Total</u> 48) Weight 14.5%	Risk Ratio M-H, Fixed, 95% Cl 1.66 [1.14, 2.42]	Risk Ratio
Test for overall effect: ned implantation Study or Subgroup Yang et al. 2012 Forman et al. 2013	Z = 4.27 (rate (> PGS-0 Events 38 54	P < 0.0 20 we CS Total 55 87	001) eks gest Contr Events 20 83	ol Total 48 172) Weight 14.5% 37.8%	Risk Ratio M-H, Fixed, 95% Cl 1.66 [1.14, 2.42] 1.29 [1.03, 1.61]	Risk Ratio M-H, Fixed, 95% Cl
Test for overall effect: ned implantation Study or Subgroup Yang et al. 2012 Forman et al. 2013 Scott et al. 2013	Z = 4.27 (rate (> PGS-0 Events 38 54 89	P < 0.0 20 we CCS Total 55 87 134	001) eks gest Contr Events 20 83 78	ol <u>Total</u> 48 172 163) 14.5% 37.8% 47.7%	Risk Ratio M-H, Fixed, 95% Cl 1.66 [1.14, 2.42] 1.29 [1.03, 1.61] 1.39 [1.14, 1.70]	Risk Ratio M-H, Fixed, 95% Cl
Test for overall effect: ned implantation Study or Subgroup Yang et al. 2012 Forman et al. 2013 Scott et al. 2013 Total (95% CI)	Z = 4.27 (rate (> PGS-C Events 38 54 89	P < 0.0 20 we CCS Total 55 87 134 276	001) eks gest Contr Events 20 83 78	ation ol <u>Total</u> 48 172 163 383) 14.5% 37.8% 47.7% 100.0%	Risk Ratio M-H, Fixed, 95% Cl 1.66 [1.14, 2.42] 1.29 [1.03, 1.61] 1.39 [1.14, 1.70] 1.39 [1.21, 1.60]	Risk Ratio M-H, Fixed, 95% Cl
Test for overall effect: ned implantation <u>Study or Subgroup</u> Yang et al. 2012 Forman et al. 2013 Scott et al. 2013 Total (95% CI) Total events	Z = 4.27 (rate (> PGS-0 Events 38 54 89 181	P < 0.0 20 we CCS Total 55 87 134 276	001) eks gest Contr Events 20 83 78 181	ol Total 48 172 163 383) 14.5% 37.8% 47.7% 100.0%	Risk Ratio M-H, Fixed, 95% Cl 1.66 [1.14, 2.42] 1.29 [1.03, 1.61] 1.39 [1.14, 1.70] 1.39 [1.21, 1.60]	Risk Ratio M-H, Fixed, 95% Cl

Dahdouh. CCS and embryo selection. Fertil Steril 2015.

Dahdouh EM et al, Fertil Steril, 2015

Guidance on the limits to the number of embryos to transfer: a committee opinion

Practice Committee of the American Society for Reproductive Medicine, and the Practice Committee of the Society for Assisted Reproductive Technology

American Society for Reproductive Medicine; and Society for Assisted Reproductive Technology, Birmingham, Alabama

TABLE 1

Recomn	nendations	for the	limit to t	he numt	berofem	ıbryos t	o transfer
--------	------------	---------	------------	---------	---------	----------	------------

		Ag	e (y)		
Prognosis	< 35	35–37	38-40	41-42	
Cleavage-stage emi Euploid Other favorable ^b All others Blastocysts ^a	oryos ^a 1 ≤2	1 1 ≤3	1 ≤3 ≤4	1 ≤4 ≤5	
Euploid	1	1	1	1	>
All others		≤2	≤2 ≤3	≤3 ≤3	

^a See text for more complete explanations.

^b Other favorable = Any ONE of these criteria: Fresh cycle: expectation of 1 or more highquality embryos available for cryopreservation, or previous live birth after an IVF cycle; FET cycle: availability of vitrified day-5 or day-6 blastocysts, euploid embryos, 1st FET cycle, or previous live birth after an IVF cycle.

Please note: Justification for transferring additional embryos beyond recommended limits should be clearly documented in the patient's medical record.

ASRM. Limits on number of embryos to transfer. Fertil Steril 2017.

Clinical PGS: Contemporary Understanding of Maternal Age and Human Embryonic Aneuploidy

Franasiak JM, Forman EJ et al, Fertil Steril, 2014. PMID: 24355045

Why do 30-40% of high-quality embryos still fail to implant?

- Embryonic factors
 - Non-genomic indels, methylation
 - Mosaicism
 - Mitochondrial function
- Uterine factors
 - Endometrial receptivity
 - Timing
 - Infection/Inflammation, Microbiome?
 - "Endometrial Disruption"
 - Endometrial contractility

Conclusions

- The future is now: the paradigm of clinical infertility care is shifting
- Healthy singleton delivery should be the goal of fertility treatment
- Blastocyst culture and synchronous transfer improves success of eSET
- Blastocyst-stage PGS and selective transfer of frozen-thawed euploid embryos enhances eSET and improves delivery outcomes after IVF

Come Visit Us in NYC!

